HIV-1 Protease Inhibitors May Interfere with the Ubiquitous Intracellular Proteases
Authors: Fehmida Visnegarwala, Daniel M. Musher, A.C. White
Journal: Annals of Internal Medicine (2001)

Letters6 November 2001HIV-1 Protease Inhibitors May Interfere with the Ubiquitous Intracellular ProteasesFehmida Visnegarwala, MD, Daniel M. Musher, MD, and A.C. White Jr., MDFehmida Visnegarwala, MDBaylor College of Medicine; Houston, TX 77030 (Visnegarwala, Musher, White Jr.)Search for more papers by this author, Daniel M. Musher, MDBaylor College of Medicine; Houston, TX 77030 (Visnegarwala, Musher, White Jr.)Search for more papers by this author, and A.C. White Jr., MDBaylor College of Medicine; Houston, TX 77030 (Visnegarwala, Musher, White Jr.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-9-200111060-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In a previous letter to the editor (1), we proposed that new-onset diabetes associated with the use of HIV-1 protease inhibitors might be caused by defective prohormone processing. We read with interest the letter from Danoff and Ling (2). Our letter stated that only in patients with a partial or complete deficiency of serine proteases PC1 and PC3 would the mammalian homologue of the yeast aspartic protease (YAP3p) be important for prohormone processing (1). At that time, we were describing diabetes with protease inhibitor use—just the first intimation of a new syndrome of lipodystrophic insulin resistance that ...References1. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy [Letter]. Ann Intern Med. 1997;127:947. [PMID: 9382374] LinkGoogle Scholar2. Danoff A, Ling WL. Protease inhibitors do not interfere with prohormone processing [Letter]. Ann Intern Med. 2000;132:330. [PMID: 10681299] LinkGoogle Scholar3. Gagnon A, Angel JB, Sorisky A. Protease inhibitors and adipocyte differentiation in cell culture [Letter]. Lancet. 1998;352:1032. [PMID: 9759749] CrossrefMedlineGoogle Scholar4. Liang JS, Distler O, Cooper DA, Stuley SL, Ginsberg HN. HIV protease inhibitors increase secretion of apolipoprotein B-lipoproteins from hepatoma cells by preventing proteasomal degradation [Abstract]. In: Program and Abstracts of the Second International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 13–15 September 2000, Toronto, Canada. Abstract 018. Google Scholar5. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:20251-4. [PMID: 10806189] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Baylor College of Medicine; Houston, TX 77030 (Visnegarwala, Musher, White Jr.) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoProtease Inhibitors Do Not Interfere with Prohormone Processing Ann Danoff and Wai Lam W. Ling Metrics Cited ByHeart positive: Design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia 6 November 2001Volume 135, Issue 9Page: 840KeywordsEnzymesHIV-1Insulin secretionLipodystrophyProhormonesProtease inhibitorsProteasesSerine proteasesSpecificitySterols ePublished: 6 November 2001 Issue Published: 6 November 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...